文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Vutrisiran对转甲状腺素蛋白淀粉样变性心肌病功能能力和生活质量的影响

Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2025-03-17

HELIOS-B试验的事后分析显示,在ATTR-CM患者中,与安慰剂相比,每12周一次皮下注射vutrisiran 25 mg持续至36个月,在30个月时更多患者维持或改善了6分钟步行距离和KCCQ总分,且预设亚组和KCCQ子域结果均支持vutrisiran。

要点

  • vutrisiran在30个月时使更多ATTR-CM患者维持或改善6分钟步行距离(所有阈值P<0.001)。
  • vutrisiran组KCCQ-OS维持或改善比例更高(>5分P<0.001,>10分P<0.01)。
  • 预设亚组和KCCQ子域变化均支持vutrisiran,单药治疗人群获益相似。

核心结论

  • 在ATTR-CM患者中,与安慰剂相比,vutrisiran在30个月时使更多患者维持或改善功能能力、健康状况和生活质量。

研究设计与样本

  • HELIOS-B试验的事后分析,患者按1:1随机接受vutrisiran 25 mg或安慰剂每12周一次,最长36个月。
  • 于基线和每6个月完成6分钟步行试验(6-MWT)和堪萨斯城心肌病问卷总分(KCCQ-OS)。

主要发现

  • 在总体人群第30个月,vutrisiran组维持或改善6-MWT距离的患者比例高于安慰剂组(>7 m:49.6% vs 33.2%;>15 m:55.5% vs 38.6%;>35 m:68.5% vs 51.6%;所有P<0.001)。
  • KCCQ-OS维持或改善(>5分:63.5% vs 46.6%,P<0.001;>10分:74.6% vs 60.7%,P<0.01)的患者比例vutrisiran组更高。
  • KCCQ子域和6-MWT、KCCQ-OS在预设亚组中从基线变化的最小二乘均值差异均支持vutrisiran。
  • 在单药治疗人群中观察到的vutrisiran获益相似。

关键数值与推荐

  • 6-MWT恶化阈值定义为较基线下降>7 m、>15 m和>35 m。
  • KCCQ-OS恶化阈值定义为较基线下降>5分和>10分。

临床怎么用

  • 对于ATTR-CM患者,vutrisiran可能有助于维持或改善功能能力和生活质量。
  • 临床评估时可结合6-MWT和KCCQ-OS动态监测治疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) progressively impairs functional capacity, health status, and quality of life (QOL). In HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), vutrisiran reduced all-cause mortality and recurrent cardiovascular events compared with placebo in patients with ATTR-CM. OBJECTIVES: This study aims to further analyze the efficacy of vutrisiran on functional capacity, health status, and QOL. METHODS: Patients were randomized 1:1 to receive vutrisiran 25 mg or placebo every 12 weeks up to 36 months. The 6-minute walk test (6-MWT) and Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) were completed at baseline and every 6 months. Cutoff values for worsening were a decrease from baseline of >7 m, >15 m, and >35 m (6-MWT), and >5 and >10 points (KCCQ-OS). Additionally, change from baseline was analyzed in prespecified subgroups and KCCQ subdomains. RESULTS: In the overall population at month 30, greater proportions of patients treated with vutrisiran vs placebo had maintained or improved 6-MWT distance according to all cutoffs analyzed (>7 m [49.6% vs 33.2%], >15 m [55.5% vs 38.6%], and >35 m [68.5% vs 51.6%]; all P < 0.001). Similarly, greater proportions of patients experienced maintenance or improvement in KCCQ-OS according to cutoff values (>5 points [63.5% vs 46.6%; P < 0.001], >10 points [74.6% vs 60.7%; P < 0.01]). Additionally, least squares mean difference in change from baseline in KCCQ subdomains, and in 6-MWT and KCCQ-OS across prespecified subgroups, favored vutrisiran vs placebo. Benefits observed with vutrisiran were similar in the monotherapy population. CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM vs placebo over 30 months.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sheikh FH, Habib G, Tang WHW, et al. Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025. PMID: 40099774. doi:10.1016/j.jacc.2025.03.454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。